News
01-30-2014, 05:41 AM
AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.
More... (http://www.news-medical.net/news/20140130/AVEO-Oncology-Astellas-Pharma-decide-to-discontinue-BATON-breast-cancer-clinical-trial.aspx)
More... (http://www.news-medical.net/news/20140130/AVEO-Oncology-Astellas-Pharma-decide-to-discontinue-BATON-breast-cancer-clinical-trial.aspx)